China Unit Of Bayer Sees Payback From R&D Investment This Year
This article was originally published in PharmAsia News
Executive SummaryThe China subsidiary of Germany's Bayer Schering Pharma AG says recent increases in research and development in China should pay off with increased sales this year
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.